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AbstrACt
Objectives To identify whether the abolition of prescription 
fees in Scotland resulted in: (1) Increase in the number (cost 
to NHS) of medicines prescribed for which there had been 
a fee (inhaled corticosteroids). (2) Reduction in hospital 
admissions for conditions related to those medications for 
which there had been a fee (asthma or chronic obstructive 
pulmonary disease (COPD))—when both are compared 
with prescribed medicines and admissions for a condition 
(diabetes mellitus) for which prescriptions were historically 
free.
Design Natural experimental retrospective general 
practice level interrupted time series (ITS) analysis using 
administrative data.
setting General practices, Scotland, UK.
Participants 732 (73.6%) general practices across Scotland 
with valid dispensed medicines and hospital admissions data 
during the study period (July 2005–December 2013).
Intervention Reduction in fees per dispensed item from 
April 2008 leading to the abolition of the fee in April 2011, 
resulting in universal free prescriptions.
Primary and secondary outcomes Hospital admissions 
recorded in the Scottish Morbidity Record – 01 Inpatient 
(SMR01) and dispensed medicines recorded in the 
Prescribing Information System (PIS).
results The ITS analysis identified marked step reductions 
in adult (19–59 years) admissions related to asthma or 
COPD (the intervention group), compared with older or young 
people with the same conditions or adults with diabetes 
mellitus (the counterfactual groups). The prescription findings 
were less coherent and subsequent sensitivity analyses 
found that both the admissions and prescriptions data were 
highly variable above the annual or seasonal level, limiting 
the ability to interpret the findings of the ITS analysis.
Conclusions This study did not find sufficient evidence that 
universal free prescriptions was a demonstrably effective or 
ineffective policy, in terms of reducing hospital admissions or 
reducing socioeconomic inequality in hospital admissions, in 
the context of a universal, publicly administered medical care 
system, the National Health Service of Scotland.
IntrODuCtIOn   
When the National Health Service (NHS) was 
founded in the UK in 1948, all the services 
provided were free. However, as early as 1950 
expenditure was higher than expected, so 
a charge (1 shilling) for prescribed items 
(including medicines, medical devices, dress-
ings, borderline substances, etc) was intro-
duced in 1952.1 This prescription fee has 
increased over time and now in England 
the charge is £8.80 per item.2 In 1968 a list 
of medical conditions for which no prescrip-
tion fee would be charged was introduced; 
these were easily recognisable, lifelong, 
life-threatening conditions that required 
regular, prescribed medication.1 Over time 
further exemptions were identified and the 
most recent list of exemption criteria is very 
extensive indeed (online supplementary file 
1).2 Now, the majority of prescriptions are 
exempt, meaning that in 2004/2005 less than 
5% of the cost of pharmaceutical services in 
Scotland was covered by the prescription fee.1 
The prescription fee has been described 
as a ‘tax on ill health’ (Nicola Sturgeon, 
then Scottish Health Secretary).3 4 Although, 
the exemption criteria (online supplemen-
tary file 1) contain many chronic diseases, 
important conditions such as asthma and 
degenerative neurological conditions are 
missing. These omissions have led many to 
strengths and limitations of this study
 ► Administrative data permitted the undertaking of a 
large long-term evaluation of a policy, which other-
wise would have been very costly and indeed, per-
haps infeasible.
 ► Data were available for over 70% of the practices in 
Scotland, which could be used to classify those who 
did and did not experience a change in prescription 
fees.
 ► The data were only available at the general practice, 
not the individual level.
 ► The time series for both admissions and prescrip-
tions were highly variable, preventing the drawing of 
specific conclusions from the evaluation.
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call for the abolition of the fee.1 5 6 In 2007 Wales was 
the first country in the UK to abolish prescription fees, 
followed by Northern Ireland in 2010 and Scotland in 
2011; a fee is still charged in England.3 Figure 1A shows 
prescription fees in England and Scotland during the 
time period examined in this study. Patients requiring 
multiple prescriptions a month could purchase a short-
term (3–4 month) or long-term (12 month) prepayment 
certificate (PPC) which provided a discount. Alongside 
the prescription fee reduction, Scotland made a marked 
reduction in PPC cost (figure 1B).
Although, the prescription fee only covers a small 
proportion of the costs of prescription services, abolishing 
the fee means that the cost needs to be met elsewhere. 
One of the justifications for abolishing prescription 
fees has been that this will lead to improved adherence 
to medication and subsequently reduced medical costs, 
through less need for expensive secondary medical care. 
Campbell et al7 found that for patients with asthma in 
USA, an increase as small as $5 in pharmacy co-payments 
resulted in reduced adherence and increased outpatient 
visits. Kulik et al8 undertook a randomised comparison 
in USA of the health impact of providing patients with 
recent myocardial infarction with free prescriptions for 
all medications, versus only a small selection of cardio-
vascular medications. It was found that full prescription 
cost coverage resulted in significantly improved adher-
ence and trends towards reductions in rates of major 
vascular events or revascularisation.8 In Canada, where all 
prescriptions are free for those over 65 years of age, health 
inequalities by socioeconomic position among those with 
diabetes are much reduced in this age group compared 
with those under 65 years of age.9 Thus far, the only 
published evaluations of the policy change across the UK 
have come from Wales and only included prescriptions 
data and anecdotal reports around other outcomes.10–13 
Hence, the intention of this study was to identify whether 
the abolition of prescription fees in Scotland resulted in 
(see online supplementary file 2 for the study protocol):
A. increase in the number (cost to NHS) of medicines 
prescribed for which there had been a fee (inhaled 
corticosteroids);
B. Reduction in hospital admissions for conditions relat-
ed to those medications for which there had been a 
fee (asthma and Chronic Obstructive Pulmonary Dis-
ease (COPD)).
The comparisons for both prescriptions and admissions 
were conditions for which prescriptions were historically 
free (diabetes mellitus, or the young or elderly). Subse-
quent research questions were:
C. Was there any change in hospital admissions in the 
practices which also saw a change in dispensing?
D. How did the effects of fee abolition differ across the 
socioeconomic spectrum?
MethODs
retrospective policy analysis
As the abolition of prescription fees had already taken 
place and was not implemented experimentally, it was 
necessary to use a natural experimental approach: inter-
rupted time series (ITS). This required historical data on 
policy exposure and outcomes.
Data
Two large administrative data sets are available in Scot-
land which made this study feasible; the Prescribing 
Information System (PIS) and the Scottish Morbidity 
Record – 01 Inpatient (SMR01). PIS is the database of all 
community prescribed and dispensed medicines across 
Scotland. SMR01 is the database of all hospital inpatient 
admissions across Scotland. Using the unique identifier, 
the Community Health Index (CHI), it is possible to link 
individual health records across health databases in Scot-
land. However, CHI has only been recorded in PIS since 
August 2009, and therefore this study was restricted to 
general practice level data. The time period examined 
in this study was July 2005 to December 2013 with fee 
Figure 1 Prescription fees in Scotland compared with England; (A) fee per item, (B) equivalent number of items purchased per 
month using prepayment certificates.
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reductions beginning in April 2008 and abolished from 
April 2011.
exposure
During study development, a group of clinicians and 
pharmacists was consulted to inform the study design, 
in particular the definition of exposure to the policy. 
Starting from the prescription fee exemption criteria 
(online supplementary file 1), groups for wom prescrip-
tions remained free (counterfactual) and became free 
(intervention) needed defining. The groups needed to 
be identifiable in PIS and SMR01 and relate to relatively 
common conditions for which non-adherence to medi-
cation would likely result in the need for hospital admis-
sion. Subsequently, the subset of pharmaceutical-sensitive 
ambulatory care-sensitive conditions was used.14 No data 
on patient financial situation is recorded in SMR01, which 
meant that intervention and counterfactual groups could 
not be defined in terms of the finance-related prescrip-
tion fee exemption criteria. Research question (D) was 
included so that some examination of the impact of 
financial situation was undertaken. Asthma and COPD, 
common adulthood conditions with condition-specific 
mediations for which the prescription fee was charged, 
were identified as the most appropriate intervention 
conditions. Diabetes mellitus, medication for which had 
been exempt from the prescription fee for many years, 
constituted the counterfactual condition. In addition to 
a condition-based counterfactual group, an age-based 
counterfactual group was used. The criteria for the 
intervention and two counterfactual groups are given in 
table 1. The need to use the exemption criteria to classify 
intervention and counterfactuals meant that dispensing 
data from PIS was used, as exemption is only recorded 
when the prescription is dispensed. This prevented the 
study’s consideration of primary non-adherence, when 
the patient does not have the prescription dispensed.
Using the exemption criteria to define the interven-
tion and counterfactual groups within the PIS presented 
a challenge, as the exemption criteria did not need 
to be recorded after the fee abolition. Fortuitously, 
exemption criteria continued to be recorded in many 
instances. The proportion of prescriptions against each 
exemption criteria was compared before and after the 
abolition, to check if reporting had changed. Apart from 
those receiving free prescriptions due to being aged 60 
years or over, reporting of exemption criteria fell mark-
edly, particularly reporting PPCs or full payment. Conse-
quently, given that Scottish Public Health Observatory 
data15–17 did not show any marked changes in the prev-
alence of asthma, COPD or diabetes during the study 
period, the proportion eligible for each exemption prior 
to the policy change was applied to the PIS data after the 
policy change. This was not an issue for the SMR-01 data, 
as the variables used to define the groups (table 1) were 
not affected by the policy change. The data sets were 
prepared, cleaned and merged in Stata18 with the top 
1% of prescription data being deleted as these very large 
values appeared to be errors (most likely due to keying 
errors during manual data entry). To make the outcomes 
comparable between groups, the primary metric of 
prescriptions used was defined daily dose (DDDs). The 
prescription cost was also examined in terms of the gross 
ingredient cost before any discounts (dispensing costs 
are met by an overall service remuneration model within 
the NHS in Scotland rather than an additional cost 
per item). Number and quantity of prescriptions were 
provided in the data set but were found not to be compa-
rable across study groups, so were not analysed. Data on 
the following characteristics of each general practice was 
also collected: health board, number of general practi-
tioners, list size (by age group), whether the practice had 
its own dispensary, the practice NHS contract type, the 
quintile of the Scottish Index of Multiple Deprivation 
(SIMD)19 of the practice postcode, the urban rural classi-
fication of the practice postcode, the number of patients 
registered at the practice living in a postcode defined as 
the 15% most deprived in Scotland, and the number of 
registered patients from each SIMD quintile and urban 
rural classification.
Table 1 Intervention and counterfactual group definitions
Prescribing Information System (PIS) Scottish Morbidity Record – 01 Inpatient (SMR01)
Intervention BNF: 3.2 Inhaled steroids
Fee: paid
Age group: >18 years to <60 years
ICD-10: J20, J40X, J41, J42, J43, J44, J45, J46 or J47
Age group: >18 years to <60 years
Condition-based 
counterfactual
BNF: 6.1.1 or 6.1.2
Fee: exempt E—medical exemption
Age group: >18 years to <60 years
ICD-10: E10, E11, E12, E13 or E14
Age group: >18 years to <60 years
Age-based 
counterfactual
BNF: 3.2 Inhaled steroids
Fee: exempt A: <16 years, B: ≥16 years to 
≤18 years and in full time education or C: 
≥60 years
Age group: <16 years, ≥16 years to ≤18 years or 
≥60 years
ICD-10: J20, J40X, J41, J42, J43, J44, J45, J46 or J47
Age group: <16 years, ≥16 years to ≤18 years or ≥60 years
BNF, British National Formulary; ICD-10, International Classification of Disease 10th version.
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Its analysis
The data set was declared a time series data set with 
monthly time periods and any missing time points within 
practices were filled with zero. As these data are related to 
instances when someone of a specific age with a specific 
condition from a specific general practice had been 
admitted to hospital or dispensed a medicine, missing 
data represent months when no prescriptions of that 
type or admissions for that condition occurred from that 
practice. Admissions included small and zero counts (eg, 
number of adult (19–59 years) asthma admissions per 
practice per month) so these data were analysed using 
mixed-effects Poisson models, offset by practice size to 
account for variations in practice size. DDDs and costs 
were transformed into DDDs or cost per 100 patients per 
practice to account for differences in practice size. The 
resulting measures were sufficiently normally distributed 
to be analysed using mixed-effects linear models. ITS 
operators were derived so that any model would fit a new 
intercept and slope at the time of the intervention, which 
could be delayed using lags. Calendar month was fitted as 
a categorical variable to account for seasonality. Finally, 
the data were treated as hierarchical with measurement 
month (i) nested within general practice (j) and the 
linear model for costs and DDDs was given by:
  
yij = β0ij + β1dateij + β2janij + β3febij + β4marij + β5mayij
+β6junij + β7julij + β8augij + β9sepij + β10octij
+β11novij + β12decij + β13reduction periodij
+β14time since reductions beganij + β15abolition periodij
+β16time since abolition beganij + ej + µij   
Where yij is the outcome for practice j at time i (in 
months), dateij is the count of months from the begin-
ning of the study period (July 2005), ej is the difference 
between the intercept for the estimated overall trend and 
the intercept for the estimated trend for practice j and μij 
is the difference between the observed outcome value for 
time i at practice j and the predicted value, and ej and μij 
are random effects. Janij to decij are dummy variables for 
each month from January to December, with April being 
the reference category as this was the month in which 
the policy changes were implemented. Reduction periodij 
and abolition periodij are dummy variables for the periods 
April 2008 to March 2011, and April 2011 to December 
2013 (the end of the study period), respectively. Time since 
reductions beganij and time since abolition beganij are counts of 
months from the beginning to end of the reduction and 
abolition periods, respectively. The meaning of the β coef-
ficients were: β0 mean outcome in July 2005 (intercept), 
β1 secular trend for time from July 2005, β2–12 mean effect 
for each month excluding April (seasonality), β13 change 
in intercept when the prescription fee was being reduced 
(reduction step change), β14 change in slope (from April 
2008 to March 2011) when the prescription fee was being 
reduced (reduction change in slope), β15 change in inter-
cept when the prescription fee was abolished (abolition 
step change) and β16 change in slope (from April 2011) 
when the prescription fee was abolished (abolition 
change in slope). The Poisson model for admissions was 
defined similarly with the logarithm of the admission rate 
expressed as a linear function of the fixed and random 
effects, and with the addition of an offset term for the 
practice size.
Admissions data were analysed with 0-month, 1-month, 
2-month and 3-month lags on the intervention effect. To 
address research question (C), it was planned that prac-
tices where changes in prescriptions and admissions consis-
tent with the hypothesised effect of the policy change be 
identified and compared as a secondary analysis. Finally, 
to address research question (D), practices whose popu-
lation modal quintile of the SIMD 201219 remained the 
same throughout the study period (constant sample size) 
were included in a repetition of the primary analysis strat-
ified by quintile of SIMD. During model development 
the hierarchical linear time series models were specified 
with first-order or second-order autoregression or moving 
averages. The results did not differ substantially between 
specifications and therefore all the results presented were 
specified with second-order moving average.
Patient and public involvement
In the early phases of development (January 2015), this 
project was presented to the public panel of the Scottish 
Farr Institute (http://www. farrinstitute. org/ farr- scot-
land). The ensuing discussion demonstrated the interest 
of the panel members in the project, which is critical for 
secondary data projects such as this, and helped shape 
the analysis and interpretation of the findings. In partic-
ular, the panel members brought to the researchers’ 
attention the issue of stockpiling of prescribed medicines 
following the fee abolition. As a secondary data analysis 
there was limited potential for public engagement during 
the conduct of the study, but the results will be dissemi-
nated to the public panel and more widely through the 
Farr Institute website.
results
Across the 8-year study period, the number of practices 
and their characteristics changed. The characteristics of 
the practices with prescriptions data at the end of the 
study period (December 2013) are presented in table 2. 
Data on prescribed medicines were available for 732 
(73.6%) of the 994 general practices across Scotland at 
the end of 2013, while admissions data were available for 
754 (75.9%) practices. The majority of practices had five 
or fewer general practitioners, fewer than 10 000 patients 
and were in urban areas. Less than 10% of practices had 
their own dispensary.
The intercept (constant) and coefficients of the ITS 
operators for the Poisson and linear mixed-effects models 
of admissions, DDDs and cost are presented in table 3. 
Throughout the results, p values have not been reported 
and the focus was on estimated effect sizes, as the size 
of the data set resulted in many statistical but not mean-
ingful significances. The intercept estimates demonstrate 
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that there were pre-existing differences in the level of 
admissions and prescriptions across the intervention and 
counterfactual groups at the start of the study period 
(July 2005). The highest rate of admissions, and number 
(DDDs) and cost of prescribed medicines were observed 
in the age-based counterfactual group, while the fewest 
admissions and prescribed medicines were seen among 
the intervention group. This demonstrates that asthma 
and COPD are, as expected, most problematic to the 
young and old. Despite these differences in quantity, 
the background secular time trend in admissions before 
the abolition of prescription fees is consistent across the 
groups. The coefficients of the ITS operators are also 
mostly consistent across groups and increasing degrees of 
time lag. A notable exception was a significant step reduc-
tion in admissions in the intervention group, related to 
the abolition of prescription fees, although the under-
lying time trend did not significantly change. The results 
regarding prescribed medicines are much less clear, with 
more marked temporal variability across the study period. 
However, the largest changes appear in the counterfac-
tual groups, indicating some phenomenon other than 
the intended effect of the policy change, which we were 
unable to identify.
The results of the analysis undertaken to examine 
whether the impact of the policy differed by socioeco-
nomic position are presented in table 4. These analyses 
aimed to assess whether the financial exemptions to the 
prescription fee (online supplementary file 1) had an 
impact on the results, as these exemptions could not 
be accounted for directly in the main analysis. Only the 
results for the intervention group have been presented, 
as individual financial position should not have had an 
impact on the counterfactual groups. The intercepts 
of the admissions analyses are consistent with known 
inequalities, with the highest rate of admissions among 
the most deprived (Q1), and the lowest rate of admissions 
in the least deprived (Q5). The results for the ITS opera-
tors are similar to the main analysis, with the most marked 
differences being observed in terms of step changes 
as opposed to changes in the underlying time trend. 
Although not statistically significant, there seems to be 
some evidence of reductions in admissions among the 
most deprived quintiles (Q1 and Q2) in relation to the 
fee-reduction policy, compared with the least deprived 
quintiles (Q4 and Q5). However, any effect is not linear 
across the SIMD quintiles. Again, the results of the anal-
ysis of prescriptions were less coherent. The intercepts 
of the models demonstrate that most paid prescriptions 
were from practices with mostly Q3 and Q4 patients, who 
are likely to have had poorer health than Q5 patients, but 
would be less likely to be eligible for free prescriptions for 
financial reasons than Q1 and Q2 patients. These quin-
tiles also demonstrate the largest step increases in DDDs 
when the fees were abolished, which is consistent with 
this being an effect of the policy.
In response to the incoherence of the findings for DDDs 
and costs and reviewer comments, several sensitivity anal-
yses were undertaken, instead of the analyses originally 
planned to address the third research question (C). First, 
using the generalised additive mixed models (GAMM) 
package in R,20–24 the models were fitted without the ITS 
operators, but by fitting eight knots evenly distributed 
Table 2 Practice characteristics in December 2013 (n=732)
Characteristic Summary statistic
Number of GPs
  ≤5 general practitioners 447 (61.1%)
  >5–≤10 general practitioners 246 (33.6%)
  >10 general practitioners 39 (5.3%)
Practice size
  ≤5000 patients 345 (47.1%)
  >5000–≤10 000 patients 305 (41.7%)
  >10 000 patients 82 (11.2%)
  Dispensing practice 67 (9.2%)
Health board
  NHS Ayrshire and Arran 37 (5.1%)
  NHS Borders 20 (2.7%)
  NHS Dumfries and Galloway 26 (3.6%)
  NHS Fife 40 (5.5%)
  NHS Forth Valley 44 (6.0%)
  NHS Grampian 37 (5.1%)
  NHS Greater Glasgow and Clyde 215 (29.4%)
  NHS Highland 72 (9.8%)
  NHS Lanarkshire 60 (8.2%)
  NHS Lothian 107 (14.6%)
  NHS Orkney 3 (0.4%)
  NHS Shetland 4 (0.5%)
  NHS Tayside 60 (8.2%)
  NHS Western Isles 7 (1.0%)
Modal SIMD quintile of patients
  Quintile 1 (most deprived) 224 (30.6%)
  Quintile 2 127 (17.3%)
  Quintile 3 155 (21.2%)
  Quintile 4 108 (14.8%)
  Quintile 5 (least deprived) 118 (16.1%)
Modal location of patients
  Large urban areas 302 (41.3%)
  Other urban areas 192 (26.2%)
  Accessible small towns 64 (8.7%)
  Remote small towns 17 (2.3%)
  Very remote small towns 9 (1.2%)
  Accessible rural 61 (8.3%)
  Remote rural 32 (4.4%)
  Very remote rural 55 (7.5%)
GP, general practitioner; NHS, National Health Service; SIMD, 
Scottish Index of Multiple Deprivation.19
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across the time series. These models allow change points 
in the time series at times other than those related to 
the policy to be revealed and relax the assumption that 
any time effects were linear. Plots of each of the models 
undertaken as part of the sensitivity analyses are shown 
in online supplementary file 3, with the dates of reduc-
tion and abolition overlaid. The admissions’ data for 
the condition-based counterfactual group show that 
following the adjustment for seasonality there was a small 
but linear increase in diabetes-related admissions among 
adults, which, as expected, appears not to change in rela-
tion to the prescription fee policy changes. However, the 
admissions’ data for the intervention-based and age-based 
counterfactual groups show marked changes which are 
neither consistent year to year, nor easily related to the 
policy changes. The patterns of admissions in both the 
intervention-based and age-based counterfactual groups 
are similar. Both the DDDs and cost of prescribed medi-
cines data for all three groups show similar patterns of 
increases, with occasional change points. These change 
points appear to be spaced in time similarly to the reduc-
tion and abolition of prescription fees, but around 12 
months after the policy changes. The magnitude of the 
changes in prescribed DDDs and costs are also greater in 
the counterfactuals than the intervention group, arguing 
against any causal effect of the intervention.
The second sensitivity analysis undertaken was to 
adjust for clustering by health board as well as general 
practice. The results of these models are presented in 
online supplementary file 4; apart from changes in the 
intercepts, the estimated coefficients did not change. As 
a third sensitivity analysis, in light of the results of the 
GAMM models, the ITS models were run with either a 
quadratic secular time effect added, or quadratic effects 
for time since reduction and time since abolition. The 
results of these models are presented in online supple-
mentary file 5 alongside plots comparing the linear and 
quadratic effects. The coefficients of the quadratic time 
effects were minimal and resulted in very few marked 
changes in the other estimated coefficients. The second 
and third sensitivity analyses demonstrate that the find-
ings of the ITS models were robust to some changes in 
the clustering of the data and time effects. However, the 
unusual trends in the time series identified within the 
first sensitivity analysis and the inconsistency between the 
findings and the hypothesised effects prevent the drawing 
of firm conclusions from this study.
DIsCussIOn
Using Scottish administrative hospital admissions and 
prescribed medicines data it was possible to undertake an 
evaluation of the impact of a major policy change. The 
evaluation included over 70% of the general practices 
in Scotland and analysed changes over an 8-year period. 
ITS analysis offered a natural experimental approach for 
evaluating the impact of policy changes which occurred 
on specific dates. There was a marked step reduction in 
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adult asthma-related or COPD-related admissions around 
the time of the abolition of prescription fees (April 2011), 
compared with the counterfactual groups. This effect 
was consistent with known health inequalities and the 
prescription fee policy prior to the change. The data on 
prescribed medicines were less coherent, with marked 
changes in the intervention and counterfactual groups. 
Sensitivity analyses revealed that there was considerable 
variation in almost all the time series that related neither 
to policy change, nor to season or annual changes. It was 
therefore difficult to draw any firm conclusions about the 
impact of the policy change.
More rigorous and conclusive results would be gener-
ated by an experimental study. However, a prospective 
study of this size and duration would have been consid-
erably more costly, and potentially impossible to fund. 
Policy changes like the one evaluated are also rarely 
introduced experimentally. The prescription fee exemp-
tion criteria, rather ironically, made this study possible. 
One challenge to this study was that the prescription fee 
exemption criteria did not need to be reported following 
the policy change, so the assumption was made that the 
proportions eligible for each exemption criteria would 
not vary markedly in the relatively short period being 
studied following the policy change. This assumption was 
supported by the finding that the proportion receiving 
free prescribed medicines due to older age remained the 
same, as these people, possibly through habit, continued 
to report their exemption. However, the variability in the 
prescription time series limited our ability to draw any 
firm conclusions regarding prescribed medicines. It is a 
weakness of the study that it was only possible to examine 
general practice-level, rather than individual-level data. 
This prevented the assessment of primary non-adherence 
and was the result of data not being collected which would 
permit individual linkage. This linkage is now possible, 
but not for the years before the policy change. Both 
SMR-01 and PIS are administrative data sets, collected for 
billing and reimbursement purposes, and therefore data 
which are most useful to research are often not collected.
Unlike previous studies on the impact of universal 
free prescriptions, it has not been possible to identify 
a clear impact of the policy change in Scotland. The 
other evaluations of prescription fees have been located 
in USA and Canada, where the health systems are quite 
different to the UK’s NHS. Kulik et al8 were able to under-
take a randomised controlled trial offering universal 
free prescriptions to patients postmyocardial infarction, 
compared with free prescriptions only for medication for 
the myocardial infarction. The participants in that study 
had a well-defined need for prescriptions, whereas in the 
current study—although the intervention group had a 
long-term condition (asthma or COPD)—the need for 
regular medication among adults with these conditions 
will vary considerably between patients. Like the current 
study, both Campbell et al7 and Booth et al9 used admin-
istrative data permitting larger retrospective studies. The 
study by Campbell et al7 is very similar to the current study 
but examined changes in monthly co-payments. They 
contrasted the impact of increases of greater or less than 
$5, which is approximately half the cost of the current 
English prescription fee. However, this was an increase 
from the average monthly co-payment of around $17, 
which is considerably larger than the English prescrip-
tion fee. Booth et al9 examined the whole population with 
diabetes over 65 years of age, who are more likely to be on 
numerous medications than the adult (19–59 years of age 
with asthma or COPD) intervention group in this study 
and therefore would have faced higher prescription costs 
in a health system where their prescriptions were not 
free. Finally, the data analysed in this study showed that 
prior to the policy change less than 13% of prescriptions 
were paid in full or by PPC. Subsequently, considering the 
proportion of that 13% that are for acute conditions, such 
as bacterial infections, this study may have been looking 
for a needle in a haystack.
Overall, in this study no marked impact of the abolition 
of prescription fees in Scotland on prescribed medicines 
or hospital admissions has been identifiable. However, 
there were some signs of some impact, specifically a step 
reduction, within 1 month of abolition, in adult admis-
sions for asthma or COPD. Although, the availability of 
administrative data made this study possible, it has also 
brought the biggest limitations to the study. As the data 
were primarily collected for administrative and finan-
cial purposes, it was understandably not optimal for this 
study, one of the most significant challenges to the use 
of big data in research.25–27 Although the PIS data were 
particularly messy, even having dropped the top 1% of 
values, the central recording of community prescriptions 
in Scotland, unlike England, made this study possible. 
This study also encountered one of the other challenges 
to research using big data, ‘over sensitivity of statistical 
hypothesis testing’.25 28 These are at least two of the topics 
for further research in the field of big data. Based on this 
study, it is not possible to conclude whether universal free 
prescription is an effective policy in terms of improving 
health or reducing inequalities; however, neither does 
the study provide evidence that the policy is ineffective. 
There has been some concern that not charging for 
prescriptions could lead to overuse or stockpiling, which 
for many medications is risky, as well as a waste of limited 
resources. The increases in prescriptions in the counter-
factual groups may support this hypothesis. Charging a 
reasonable fee per prescription may limit this; however, 
the size of the fee required to cover the administrative 
costs of the payment system may lead to the fee being 
high enough to inappropriately limit pharmaceutical 
use. Rigorous evaluation needs to accompany any health 
policy changes to inform our understanding of the most 
efficient health systems and services.
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